EISAI CO
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT04078295
- Locations
- π―π΅
Eisai Trial Site #11, Akashi, Hyogo, Japan
π―π΅Eisai Trial Site #18, Kashiwa City, Chiba, Japan
π―π΅Eisai Trial Site #2, Kashiwa, Chiba, Japan
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 412
- Registration Number
- NCT04008082
- Locations
- π―π΅
Eisai Trial Site #2, Tokyo, Japan
π―π΅Eisai Trial Site #1, Osaka, Japan
A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03885882
- Locations
- π³πΏ
Auckland Clinical Studies, Auckland, New Zealand
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
- Conditions
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03833700
- Locations
- π―π΅
Eisai Trial Site#8, Sendai, Miyagi, Japan
π―π΅Eisai Trial Site #5, Sapporo, Hokkaido, Japan
π―π΅Eisai Trial Site #4, Fukuoka, Japan
Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03780907
- Locations
- π©πͺ
3ClinicalResearch AG, Hennigsdorf, Germany
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03754582
- Locations
- π―π΅
Eisai trial site 9, Omura, Nagasaki, Japan
π―π΅Eisai trial site 10, Hiroshima, Japan
π―π΅Eisai trial site 4, Yamagata, Japan
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03456726
- Locations
- π―π΅
1028 Eisai Trial Site, Yokohama, Kanagawa, Japan
π―π΅1001 Eisai Trial Site, Chuo-ku, Tokyo, Japan
π―π΅1011 Eisai Trial Site, Hiroshima, Japan
A Study of E7130 in Participants With Solid Tumors
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 95
- Registration Number
- NCT03444701
- Locations
- π―π΅
Eisai Trial Site 9, Nagoya, Aichi, Japan
π―π΅Eisai Trial Site 8, Sapporo, Hokkaido, Japan
π―π΅Eisai Trial Site 4, Sendai, Miyagi, Japan
Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT03424564
- Locations
- π¨π³
Eisai Trial Site, Beijing, Beijing, China
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03418922
- Locations
- π―π΅
Eisai Trial Site 3, Kawasaki, Kanagawa, Japan
π―π΅Eisai Trial Site 1, Kashiwa, Chiba, Japan
π―π΅Eisai Trial Site 6, Iizuka, Fukuoka, Japan